{"id":1344,"date":"2026-11-16T14:35:09","date_gmt":"2026-11-16T12:35:09","guid":{"rendered":"https:\/\/www.pqra.gr\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/"},"modified":"2026-11-16T14:37:17","modified_gmt":"2026-11-16T12:37:17","slug":"drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/","title":{"rendered":"Drug Substance Characterisation and Impurities in 3.2.S.3: Applying ICH Q3A and M7"},"content":{"rendered":"<p style=\"font-size:19px;line-height:1.7;color:#33414d;\"><strong>Section 3.2.S.3 is where the applicant proves it knows exactly what the active substance is and what else comes with it. A thorough impurity discussion, grounded in ICH Q3A(R2) and ICH M7, is one of the strongest signals of dossier quality an assessor can find.<\/strong><\/p>\n<h2>Two parts, one argument<\/h2><p>The section has two components:<\/p><ul><li><strong>3.2.S.3.1 Elucidation of structure and other characteristics:<\/strong> confirmation of structure using appropriate techniques, together with properties such as isomerism, polymorphism and particle size where they matter for the product.<\/li><li><strong>3.2.S.3.2 Impurities:<\/strong> a discussion of actual and potential impurities arising from synthesis, degradation and storage, including residual solvents and inorganic impurities.<\/li><\/ul><p>The impurity discussion should connect directly to the route of synthesis in 3.2.S.2 and to the specification in 3.2.S.4.<\/p><h2>The ICH Q3A(R2) thresholds<\/h2><p>For new active substances, ICH Q3A(R2) sets reporting, identification and qualification thresholds based on maximum daily dose. For a maximum daily dose of up to 2 g, these are:<\/p><ul><li>reporting: 0.05%;<\/li><li>identification: 0.10% or 1.0 mg per day intake, whichever is lower;<\/li><li>qualification: 0.15% or 1.0 mg per day intake, whichever is lower.<\/li><\/ul><p>Impurities above the qualification threshold need safety justification, whether through nonclinical data, literature or their presence at comparable levels in batches used in safety and clinical studies.<\/p><h2>Mutagenic impurities under ICH M7<\/h2><p>ICH M7(R2) requires a separate assessment of impurities with mutagenic potential. Applicants are expected to identify actual and potential impurities, assess them using (Q)SAR methodologies and expert review, classify them, and set a control strategy. For lifetime exposure, the threshold of toxicological concern of 1.5 \u00b5g per day is the usual starting point, with compound-specific limits where data allow. Purge arguments can support controlling an impurity upstream rather than testing it in the final substance, but they must be scientifically reasoned.<\/p><h2>Where dossiers fall short<\/h2><ul><li>Potential impurities from starting materials and reagents not discussed.<\/li><li>Degradation pathways asserted rather than supported by forced degradation data.<\/li><li>Specification limits set at the qualification threshold without batch data to show they are achievable.<\/li><li>An ICH M7 assessment presented as a table with no explanation of the expert review.<\/li><\/ul><p>Where an ASMF or CEP is used, the applicant still needs to ensure that the impurity information available to the authority supports the finished product.<\/p><h2>How PQRA helps<\/h2><p>PQRA reviews drug substance sections and impurity assessments, checks alignment between route, impurity discussion and specification, and prepares responses when authorities question impurity control.<\/p><p><a href=\"\/el\/contact\/\">Contact PQRA<\/a> to discuss your next dossier.<\/p>","protected":false},"excerpt":{"rendered":"<p>Section 3.2.S.3 is where the applicant proves it knows exactly what the active substance is and what else comes with it. A thorough impurity discussion, grounded in ICH Q3A(R2) and ICH M7, is one of the strongest signals of dossier quality an assessor can find. Two parts, one argument The section has two components: 3.2.S.3.1 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1358,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"saved_in_kubio":false,"_swpsp_post_exclude":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1344","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Drug Substance Characterisation and Impurities in 3.2.S.3: Applying ICH Q3A and M7 - PQRA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pqra.gr\/el\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/\" \/>\n<meta property=\"og:locale\" content=\"el_GR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug Substance Characterisation and Impurities in 3.2.S.3: Applying ICH Q3A and M7 - PQRA\" \/>\n<meta property=\"og:description\" content=\"Section 3.2.S.3 is where the applicant proves it knows exactly what the active substance is and what else comes with it. A thorough impurity discussion, grounded in ICH Q3A(R2) and ICH M7, is one of the strongest signals of dossier quality an assessor can find. Two parts, one argument The section has two components: 3.2.S.3.1 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pqra.gr\/el\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/\" \/>\n<meta property=\"og:site_name\" content=\"PQRA\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T12:35:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-16T12:37:17+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u03bb\u03b5\u03c0\u03c4\u03ac\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\"},\"headline\":\"Drug Substance Characterisation and Impurities in 3.2.S.3: Applying ICH Q3A and M7\",\"datePublished\":\"2026-11-16T12:35:09+00:00\",\"dateModified\":\"2026-11-16T12:37:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\\\/\"},\"wordCount\":419,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/module-3-2-s-3-impurities.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\\\/\",\"name\":\"Drug Substance Characterisation and Impurities in 3.2.S.3: Applying ICH Q3A and M7 - PQRA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/module-3-2-s-3-impurities.png\",\"datePublished\":\"2026-11-16T12:35:09+00:00\",\"dateModified\":\"2026-11-16T12:37:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\\\/#breadcrumb\"},\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/module-3-2-s-3-impurities.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/module-3-2-s-3-impurities.png\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pqra.gr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Drug Substance Characterisation and Impurities in 3.2.S.3: Applying ICH Q3A and M7\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"name\":\"PQRA\",\"description\":\"Your trusted partner in Pharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pqra.gr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"el\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\",\"name\":\"PQRA\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"width\":594,\"height\":362,\"caption\":\"PQRA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.pqra.gr\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Drug Substance Characterisation and Impurities in 3.2.S.3: Applying ICH Q3A and M7 - PQRA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pqra.gr\/el\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/","og_locale":"el_GR","og_type":"article","og_title":"Drug Substance Characterisation and Impurities in 3.2.S.3: Applying ICH Q3A and M7 - PQRA","og_description":"Section 3.2.S.3 is where the applicant proves it knows exactly what the active substance is and what else comes with it. A thorough impurity discussion, grounded in ICH Q3A(R2) and ICH M7, is one of the strongest signals of dossier quality an assessor can find. Two parts, one argument The section has two components: 3.2.S.3.1 [&hellip;]","og_url":"https:\/\/www.pqra.gr\/el\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/","og_site_name":"PQRA","article_published_time":"2026-11-16T12:35:09+00:00","article_modified_time":"2026-11-16T12:37:17+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc":"admin","\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2":"2 \u03bb\u03b5\u03c0\u03c4\u03ac"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pqra.gr\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/#article","isPartOf":{"@id":"https:\/\/www.pqra.gr\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/"},"author":{"name":"admin","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c"},"headline":"Drug Substance Characterisation and Impurities in 3.2.S.3: Applying ICH Q3A and M7","datePublished":"2026-11-16T12:35:09+00:00","dateModified":"2026-11-16T12:37:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pqra.gr\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/"},"wordCount":419,"commentCount":0,"publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"image":{"@id":"https:\/\/www.pqra.gr\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/module-3-2-s-3-impurities.png","articleSection":["Uncategorized"],"inLanguage":"el","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.pqra.gr\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.pqra.gr\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/","url":"https:\/\/www.pqra.gr\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/","name":"Drug Substance Characterisation and Impurities in 3.2.S.3: Applying ICH Q3A and M7 - PQRA","isPartOf":{"@id":"https:\/\/www.pqra.gr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pqra.gr\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/#primaryimage"},"image":{"@id":"https:\/\/www.pqra.gr\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/module-3-2-s-3-impurities.png","datePublished":"2026-11-16T12:35:09+00:00","dateModified":"2026-11-16T12:37:17+00:00","breadcrumb":{"@id":"https:\/\/www.pqra.gr\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/#breadcrumb"},"inLanguage":"el","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pqra.gr\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/"]}]},{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/#primaryimage","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/module-3-2-s-3-impurities.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/module-3-2-s-3-impurities.png","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.pqra.gr\/drug-substance-characterisation-and-impurities-in-3-2-s-3-applying-ich-q3a-and-m7\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pqra.gr\/"},{"@type":"ListItem","position":2,"name":"Drug Substance Characterisation and Impurities in 3.2.S.3: Applying ICH Q3A and M7"}]},{"@type":"WebSite","@id":"https:\/\/www.pqra.gr\/#website","url":"https:\/\/www.pqra.gr\/","name":"PQRA","description":"Your trusted partner in Pharma","publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pqra.gr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"el"},{"@type":"Organization","@id":"https:\/\/www.pqra.gr\/#organization","name":"PQRA","url":"https:\/\/www.pqra.gr\/","logo":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","width":594,"height":362,"caption":"PQRA"},"image":{"@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c","name":"admin","image":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.pqra.gr"]}]}},"_links":{"self":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/comments?post=1344"}],"version-history":[{"count":1,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1344\/revisions"}],"predecessor-version":[{"id":1359,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1344\/revisions\/1359"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media\/1358"}],"wp:attachment":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media?parent=1344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/categories?post=1344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/tags?post=1344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}